| Name | Recombinant Human CLEC9a Fc Chimera Protein, CF |
|---|---|
| Supplier | R&D Systems |
| Catalog | 6049-CL |
| Category | Protein |
| Prices | $329.00 |
| Sizes | 50 µg |
| Species Reactivities | Human |
| Nature | Recombinant |
| Source | Mouse myeloma cell line, NS0-derived Met-Asp Human IgG 1 (Pro100-Lys330) IEGR Human CLEC9a (Lys57-Val241) Accession # Q6UXN8 N-terminus C-terminus |
| Purity | >95%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
| Bioactivity | Measured by flow cytometry for its ability to bind a ligand expressed in FasL-treated mouse B cells. Sancho, D. et al . (2009) Nature 458 :899. At 100 ng/mL, >50% of necrotic cells bind to Recombinant Human CLEC9a. |
| Endotoxin | <0.10 EU per 1 μg of the protein by the LAL method. |
| SwissProt/Accession | Q6UXN8 |
| Gene | CLEC9A |
| Sequence | Met |
| Supplier Page | Shop |
Uto T, Fukaya T, Takagi H, Arimura K, Nakamura T, Kojima N, Malissen B, Sato K. Nat Commun. 2016 Apr 12;7:11273.
Iborra S, Izquierdo HM, Martinez-Lopez M, Blanco-Menendez N, Reis e Sousa C, Sancho D. J Clin Invest. 2012 May;122(5):1628-43.